Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics Inc (NASDAQ: CAPR) is a clinical-stage biotechnology leader advancing novel cell and exosome-based therapies for rare diseases. This dedicated news hub provides investors and researchers with essential updates on therapeutic developments, regulatory milestones, and scientific advancements.
Discover comprehensive coverage of CAP-1002 clinical progress for Duchenne muscular dystrophy, StealthXTM platform innovations, and strategic partnerships driving next-generation treatments. Our curated repository ensures access to verified press releases and objective reporting on critical developments in cardiac cell therapies and exosome delivery systems.
Key updates include clinical trial phases, peer-reviewed research publications, manufacturing advancements, and regulatory interactions. Bookmark this page for real-time tracking of Capricor's progress in redefining regenerative medicine through rigorous scientific validation and targeted therapeutic approaches.
Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a preclinical study in Microbiology Spectrum, showcasing the potential of its StealthX™ exosome platform to develop a multivalent vaccine targeting SARS-CoV-2 proteins. The study indicates that engineered exosomes expressing SARS-CoV-2 spike and nucleocapsid proteins can induce strong immune responses. Notably, the combination approach (STX-S+N) demonstrated robust antibody production and T-cell response with minimal protein doses, lacking adjuvants. CEO Linda Marbán highlighted the significance of this platform in generating potentially superior vaccines. The results support further exploration of the StealthX™ platform in expanding Capricor's therapeutic pipeline, especially concerning rapidly evolving viruses.
Capricor Therapeutics (NASDAQ: CAPR) reported promising 18-month results from its HOPE-2 open-label extension study for CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). Presented by Dr. Craig McDonald at the Muscular Dystrophy Association Clinical & Scientific Conference, the findings show statistically significant improvements in the Performance of the Upper Limb (PUL version 2.0) scale (p=0.02) compared to the placebo group. Both groups showed reduced disease progression after starting treatment. CAP-1002 maintained a good safety profile, and the study indicates potential long-term benefits for patients. The company is advancing to the HOPE-3 Phase 3 trial.
FAQ
What is the current stock price of Capricor Therapeutics (CAPR)?
What is the market cap of Capricor Therapeutics (CAPR)?
